Geron Corp GERN:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD

Last | 12:26 PM EDT

3.52

+0.06 (+1.88%)

Volume

1,953,121

52 week range

1.64 - 4.05

Open3.45
Day High3.56
Day Low3.42
Prev Close3.45
52 Week High4.05
52 Week High Date04/12/24
52 Week Low1.64
52 Week Low Date03/13/24

Key Stats

Market Cap2.063B
Shares Out586.91M
10 Day Average Volume12.24M
Dividend-
Dividend Yield-
Beta0.59
YTD % Change66.35

KEY STATS

Open3.45
Day High3.56
Day Low3.42
Prev Close3.45
52 Week High4.05
52 Week High Date04/12/24
52 Week Low1.64
52 Week Low Date03/13/24
Market Cap2.063B
Shares Out586.91M
10 Day Average Volume12.24M
Dividend-
Dividend Yield-
Beta0.59
YTD % Change66.35

RATIOS/PROFITABILITY

EPS (TTM)-0.32
P/E (TTM)-10.83
Fwd P/E (NTM)-10.52
EBITDA (TTM)-193.502M
ROE (TTM)-112.29%
Revenue (TTM)237,000.003
Gross Margin (TTM)-
Net Margin (TTM)-77,690.72%
Debt To Equity (MRQ)33.05%

EVENTS

Earnings Date05/09/2024(est)
Ex Div Date-
Div Amount-
Split Date-
Split Factor-

Latest On Geron Corp

Cramer's Lightening Round: BTU, TTD, GERNApril 10, 2024CNBC.com
Cramer's Lightning Round: Trade Desk is 'great'April 10, 2024CNBC.com

Content From Our Affiliates

Buy Rating Affirmed for Geron Following Insightful Leadership Discussion and Promising Drug Development ProgressApril 11, 2024TipRanks
Analysts Offer Insights on Healthcare Companies: Carl Zeiss Meditec (GB:0DHC), Geron (GERN) and Zur Rose Group AG (Six Swiss: CH:DOCM)April 11, 2024TipRanks
Geron prices $150M offering of common stock and warrants at $3.00 per shareMarch 19, 2024TipRanks
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and Geron (GERN)March 19, 2024TipRanks
Biotech Alert: Searches spiking for these stocks todayMarch 18, 2024TipRanks

Profile

Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical...

John Scarlett M.D.

Chairman of the Board, President, Chief Executive Officer

Andrew Grethlein Ph.D.

Executive Vice President, Chief Operating Officer

Michelle Robertson

Chief Financial Officer, Executive Vice President, Treasurer

Stephen Rosenfield J.D.

Executive Vice President, Corporate Secretary, Chief Legal Officer

Anil Kapur

Executive Vice President, Corporate Strategy and Chief Commercial Officer

Address

919 East Hillsdale Boulevard, Suite 250

Foster City, CA

94404

United States

https://www.geron.com/

Top Peers

SYMBOL	LAST	CHG	%CHG
VERA Vera Therapeutics Inc	46.28	-0.25	-0.54%
KROS Keros Therapeutics Inc	58.08	+0.40	+0.68%
RCKT Rocket Pharmaceuticals Inc	24.01	UNCH	UNCH
CLDX Celldex Therapeutics Inc	38.75	-0.32	-0.82%
DYN Dyne Therapeutics Inc	24.98	-0.46	-1.83%